Seminars in Cancer Biology

(The TQCC of Seminars in Cancer Biology is 34. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)
Ferroptosis is a type of autophagy-dependent cell death546
Natural products targeting the PI3K-Akt-mTOR signaling pathway in cancer: A novel therapeutic strategy258
Natural product-based nanoformulations for cancer therapy: Opportunities and challenges224
The role of SOX family members in solid tumours and metastasis208
Specific targeting cancer cells with nanoparticles and drug delivery in cancer therapy194
Cancer-associated fibroblasts in desmoplastic tumors: emerging role of integrins178
Emerging roles of ECM remodeling processes in cancer177
SOX2 in development and cancer biology175
Radiomics in breast cancer classification and prediction170
Targeting p53 for the treatment of cancer167
Evolving concepts in HER2 evaluation in breast cancer: Heterogeneity, HER2-low carcinomas and beyond160
Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression157
Attacking the PI3K/Akt/mTOR signaling pathway for targeted therapeutic treatment in human cancer153
The emerging, multifaceted role of mitophagy in cancer and cancer therapeutics151
Risk of colorectal cancer in inflammatory bowel diseases142
Immune checkpoints in the tumor microenvironment134
Autoimmunity, checkpoint inhibitor therapy and immune-related adverse events: A review133
Curcumin and colorectal cancer: An update and current perspective on this natural medicine133
Targeting cancer cells with nanotherapeutics and nanodiagnostics: Current status and future perspectives131
An update on vitamin D signaling and cancer130
Artificial intelligence for breast cancer detection in mammography and digital breast tomosynthesis: State of the art126
Machine and deep learning approaches for cancer drug repurposing123
Flavonoids nanoparticles in cancer: Treatment, prevention and clinical prospects121
lncRNA involvement in cancer stem cell function and epithelial-mesenchymal transitions121
Revisiting the hallmarks of cancer: The role of hyaluronan119
RAF-MEK-ERK pathway in cancer evolution and treatment119
Regulation of autophagy by canonical and non-canonical ER stress responses118
Mitochondrial mutations and mitoepigenetics: Focus on regulation of oxidative stress-induced responses in breast cancers117
Pathology of triple negative breast cancer115
The CXCL12-CXCR4/CXCR7 axis as a mechanism of immune resistance in gastrointestinal malignancies113
SOX4: The unappreciated oncogene112
Dietary fat, bile acid metabolism and colorectal cancer108
Ferroptosis, necroptosis, and pyroptosis in the tumor microenvironment: Perspectives for immunotherapy of SCLC108
The complexity of p53-mediated metabolic regulation in tumor suppression101
An updated overview on metal nanoparticles toxicity98
Repurposing of drugs: An attractive pharmacological strategy for cancer therapeutics98
Regulation and function of SOX9 during cartilage development and regeneration97
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer96
Precision medicine in non-small cell lung cancer: Current applications and future directions94
Nanoparticles-based drug delivery and gene therapy for breast cancer: Recent advancements and future challenges94
PROTACs: A novel strategy for cancer therapy93
Laminin 332 in cancer: When the extracellular matrix turns signals from cell anchorage to cell movement92
Artificial intelligence aids in development of nanomedicines for cancer management91
Combining epigenetic and immune therapy to overcome cancer resistance90
Molecular mechanisms of pulmonary carcinogenesis by polycyclic aromatic hydrocarbons (PAHs): Implications for human lung cancer90
Thyroid autoimmune disorders and cancer88
DNMT1: A key drug target in triple-negative breast cancer87
Antibody therapeutics and immunoregulation in cancer and autoimmune disease87
Applications and strategies in nanodiagnosis and nanotherapy in lung cancer87
Molecular mechanisms of action of epigallocatechin gallate in cancer: Recent trends and advancement86
The Skp2 Pathway: A Critical Target for Cancer Therapy85
RNA methylations in human cancers84
The balance between breast cancer and the immune system: Challenges for prognosis and clinical benefit from immunotherapies81
Tumor intrinsic and extrinsic immune functions of CD15581
Epithelial-to-mesenchymal transition and invadopodia markers in breast cancer: Lumican a key regulator81
The impact of VEGF on cancer metastasis and systemic disease81
Targeting hypoxia-inducible factor-1, for cancer treatment: Recent advances in developing small-molecule inhibitors from natural compounds80
Chemotherapeutic efficacy of curcumin and resveratrol against cancer: Chemoprevention, chemoprotection, drug synergism and clinical pharmacokinetics79
Epigenetics of glioblastoma multiforme: From molecular mechanisms to therapeutic approaches79
The oral microbiota and its role in carcinogenesis78
Targeting STAT3 signaling pathway in cancer by agents derived from Mother Nature78
Neutrophil extracellular traps in cancer77
Ginger and its active compounds in cancer therapy: From folk uses to nano-therapeutic applications76
Recent insight into the role of FBXW7 as a tumor suppressor74
Drug repurposing for breast cancer therapy: Old weapon for new battle74
Anticancer potential of garlic and its bioactive constituents: A systematic and comprehensive review73
Anti-inflammatory and anti-cancer activities of frankincense: Targets, treatments and toxicities73
Epidemiology of breast cancer, a paradigm of the “common soil” hypothesis70
Immune checkpoint proteins: Signaling mechanisms and molecular interactions in cancer immunotherapy69
NEDD4 E3 ligase: Functions and mechanism in human cancer69
Cancer immunotherapy with check point inhibitor can cause autoimmune adverse events due to loss of Treg homeostasis69
Phytochemicals in cancer cell chemosensitization: Current knowledge and future perspectives69
EGFR signaling pathway as therapeutic target in human cancers68
Epigenetics in hepatocellular carcinoma68
Dissenting degradation: Deubiquitinases in cell cycle and cancer68
Dietary flavonoids: Nano delivery and nanoparticles for cancer therapy67
TGF-β in developmental and fibrogenic EMTs67
PD-L1 status in breast cancer: Current view and perspectives66
Exosomes and extracellular vesicles: Rethinking the essential values in cancer biology66
Colorectal cancer occurrence and treatment based on changes in intestinal flora66
Emerging roles of long noncoding RNAs in chemoresistance of pancreatic cancer65
Extracellular vesicles in cancer nanomedicine65
Autophagy-modulating phytochemicals in cancer therapeutics: Current evidences and future perspectives65
Predictive biomarkers for response to immune checkpoint inhibition64
SOX4: Epigenetic regulation and role in tumorigenesis64
At a glance: A history of autophagy and cancer64
Circular RNAs in cancer: Limitations in functional studies and diagnostic potential64
Challenges and pitfalls in the development of liposomal delivery systems for cancer therapy62
Role of LDH in tumor glycolysis: Regulation of LDHA by small molecules for cancer therapeutics62
Functionalized mesoporous silica nanoparticles in anticancer therapeutics62
Molecular targets of tyrosine kinase inhibitors in thyroid cancer62
Hedgehog signaling mechanism and role in cancer60
The potential of liquid biopsy in the management of cancer patients60
Connections between endoplasmic reticulum stress-associated unfolded protein response, mitochondria, and autophagy in arsenic-induced carcinogenesis60
Computer-aided drug repurposing for cancer therapy: Approaches and opportunities to challenge anticancer targets60
Nanomedicine in treatment of breast cancer – A challenge to conventional therapy59
The functions and regulation of Smurfs in cancers59
Cancer cell heterogeneity & plasticity in glioblastoma and brain tumors58
Integrating tumor hypoxic stress in novel and more adaptable strategies for cancer immunotherapy57
Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress56
Chemotherapy resistance in epithelial ovarian cancer: Mechanisms and emerging treatments56
Determinants of response and resistance to CAR T cell therapy56
Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer56
Solid stress, competition for space and cancer: The opposing roles of mechanical cell competition in tumour initiation and growth56
Role of heparanase in tumor progression: Molecular aspects and therapeutic options55
Tumor glycolysis, an essential sweet tooth of tumor cells55
APC/C ubiquitin ligase: Functions and mechanisms in tumorigenesis55
Oncogenic signaling pathways associated with immune evasion and resistance to immune checkpoint inhibitors in cancer54
Role of iron in cancer54
Cellular heterogeneity and plasticity in liver cancer54
Role of cell surface proteoglycans in cancer immunotherapy54
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer54
Engineered nanoparticles for imaging and drug delivery in colorectal cancer54
Repurposing of drugs as STAT3 inhibitors for cancer therapy54
Circular RNAs as biomarkers and therapeutic targets in cancer53
Chemokines in colon cancer progression53
Toll-like receptor-induced cytokines as immunotherapeutic targets in cancers and autoimmune diseases52
RBR E3 ubiquitin ligases in tumorigenesis52
Epigenetic modifications of c-MYC: Role in cancer cell reprogramming, progression and chemoresistance52
The intricacies of NRF2 regulation in cancer51
Mechanisms of cancer metastasis51
miRNA dysregulation is an emerging modulator of genomic instability51
Systems biology based drug repositioning for development of cancer therapy51
Slow-cycling (dormant) cancer cells in therapy resistance, cancer relapse and metastasis51
Nanoparticle mediated cancer immunotherapy50
Intracellular hyaluronan: Importance for cellular functions49
Repurposing quinacrine for treatment-refractory cancer49
AMPK signaling and its targeting in cancer progression and treatment49
Implications of nanotechnology for the treatment of cancer: Recent advances49
Nano-immunotherapy: Overcoming tumour immune evasion48
Glyco-nanoparticles: New drug delivery systems in cancer therapy48
Anticancer activity of lactic acid bacteria47
The development and progress of nanomedicine for esophageal cancer diagnosis and treatment47
Epigenetic underpinnings of inflammation: Connecting the dots between pulmonary diseases, lung cancer and COVID-1947
Effects of statins on brain tumors: a review47
The role of senescence in cancer development47
Repurposing of plant alkaloids for cancer therapy: Pharmacology and toxicology47
Biological functions of therapy-induced senescence in cancer46
Modulation of dysregulated cancer metabolism by plant secondary metabolites: A mechanistic review46
Path of Silibinin from diet to medicine: A dietary polyphenolic flavonoid having potential anti-cancer therapeutic significance46
Advancement of cancer immunotherapy using nanoparticles-based nanomedicine45
RNA-binding proteins and cancer metastasis45
Targeted delivery of miRNA based therapeuticals in the clinical management of Glioblastoma Multiforme44
Targeting OXPHOS and the electron transport chain in cancer; Molecular and therapeutic implications44
How far have we explored fungi to fight cancer?44
Regulatory roles for SOX11 in development, stem cells and cancer44
Recent insights into apoptosis and toxic autophagy: The roles of MDA-7/IL-24, a multidimensional anti-cancer therapeutic44
‘Warburg effect’ controls tumor growth, bacterial, viral infections and immunity – Genetic deconstruction and therapeutic perspectives44
Artificial intelligence-based multi-omics analysis fuels cancer precision medicine44
Probiotics in microbiome ecological balance providing a therapeutic window against cancer43
Epithelial defense against cancer (EDAC)43
Danger matrix molecules orchestrate CD14/CD44 signaling in cancer development42
Emerging roles of long non-coding RNAs in breast cancer biology and management42
Dysregulated FOXM1 signaling in the regulation of cancer stem cells42
Noncoding RNAs as potential mediators of resistance to cancer immunotherapy42
Turning liabilities into opportunities: Off-target based drug repurposing in cancer42
Exposing Hidden Targets: Combining epigenetic and immunotherapy to overcome cancer resistance41
Extracellular vesicles as natural therapeutic agents and innate drug delivery systems for cancer treatment: Recent advances, current obstacles, and challenges for clinical translation41
Artificial intelligence and pathology: From principles to practice and future applications in histomorphology and molecular profiling41
The genomic landscape of pediatric acute lymphoblastic leukemia and precision medicine opportunities41
Artificial intelligence in lung cancer diagnosis and prognosis: Current application and future perspective40
The role of cell signaling in the crosstalk between autophagy and apoptosis in the regulation of tumor cell survival in response to sorafenib and neratinib40
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy40
Polyploidy formation in cancer cells: How a Trojan horse is born40
Cancer stem cells in TNBC39
Epithelial-mesenchymal transition: Insights into nickel-induced lung diseases39
Heterogeneity and plasticity of cancer-associated fibroblasts in the pancreatic tumor microenvironment39
Cullin-RING Ligase 5: Functional characterization and its role in human cancers39
Small cell lung cancer transformation: From pathogenesis to treatment39
Nanotechnological based miRNA intervention in the therapeutic management of neuroblastoma39
The evolutionary legacy of immune checkpoint inhibitors39
Epigenetic modifications of autophagy in cancer and cancer therapeutics39
Repurposing drugs in oncology: From candidate selection to clinical adoption39
Recent trends and advances in the epidemiology, synergism, and delivery system of lycopene as an anti-cancer agent39
Repurposing antipsychotics of the diphenylbutylpiperidine class for cancer therapy39
The IGF2BP family of RNA binding proteins links epitranscriptomics to cancer39
Uveal melanoma pathobiology: Metastasis to the liver38
Molecular pathogenesis, targeted therapies, and future perspectives for gastric cancer38
Interference between copper transport systems and platinum drugs38
Genome chaos: Creating new genomic information essential for cancer macroevolution38
Integrated approaches for precision oncology in colorectal cancer: The more you know, the better38
The pleiotropic role of proteoglycans in extracellular vesicle mediated communication in the tumor microenvironment38
Molecular, cellular and systemic aspects of epithelial ovarian cancer and its tumor microenvironment37
Paradoxes of cancer: Survival at the brink37
Extracellular vesicles, the cornerstone of next-generation cancer diagnosis?37
Cyclin D degradation by E3 ligases in cancer progression and treatment37
Gold nanoparticles and cancer: Detection, diagnosis and therapy37
New Advances in Molecular Breast Cancer Pathology37
The hallmarks of ovarian cancer stem cells and niches: Exploring their harmonious interplay in therapy resistance37
Targeting NRF2 to treat cancer37
ITCH as a potential therapeutic target in human cancers37
Chemokines in triple-negative breast cancer heterogeneity: New challenges for clinical implications36
Fibroblast heterogeneity in solid tumors: From single cell analysis to whole-body imaging36
Tumor microenvironment and cellular senescence: Understanding therapeutic resistance and harnessing strategies36
MicroRNA and ER stress in cancer36
Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy36
SOX17 in cellular reprogramming and cancer36
Long non-coding RNA and RNA-binding protein interactions in cancer: Experimental and machine learning approaches36
Vimentin and cytokeratin: Good alone, bad together36
Emerging applications of bacteria as antitumor agents36
Targeting integrins for cancer management using nanotherapeutic approaches: Recent advances and challenges36
Cancer epigenetics: Past, present and future35
Roles of microbiota in response to cancer immunotherapy35
Organically derived exosomes as carriers of anticancer drugs and imaging agents for cancer treatment35
Natural compounds modulate the crosstalk between apoptosis- and autophagy-regulated signaling pathways: Controlling the uncontrolled expansion of tumor cells35
Vaginal microbiome and cervical cancer35
Multiple endocrine neoplasia type 2: A review34
Dissecting miRNA facilitated physiology and function in human breast cancer for therapeutic intervention34
Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer34
Clinical utility of whole-genome sequencing in precision oncology34
Pro-survival autophagy: An emerging candidate of tumor progression through maintaining hallmarks of cancer34
Cancer cells employ an evolutionarily conserved polyploidization program to resist therapy34
Progress and promises of epigenetic drugs and epigenetic diets in cancer prevention and therapy: A clinical update34
Epigenetic and breast cancer therapy: Promising diagnostic and therapeutic applications34